Madopar Hbs

Levodopa / Benserazide, the active ingredient in Madopar Hbs, is a dopamine precursor and DOPA decarboxylase inhibitor presented as an oral tablet formulation for oral administration. It is indicated for the management of Parkinson's disease and Parkinsonian syndrome, improving motor function by increasing central dopamine levels while minimizing peripheral side effects and improving overall tolerability.

GNH USA supplies Madopar Hbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance for EU‑origin medicines through robust supply chain management and dedicated customer support.

Madopar Hbs, a combination of levodopa and benserazide, acts on the dopaminergic pathway to treat Parkinsonian disorders.

- Parkinson's disease: improves overall motor function, reducing tremor, rigidity, bradykinesia and improving gait and daily activity performance. - Parkinsonian syndrome: alleviates motor symptoms such as rigidity, tremor and bradykinesia that arise in secondary Parkinsonism, enhancing patient mobility. - Motor fluctuations in Parkinson's disease: helps reduce OFF periods, smoothens the response to levodopa therapy and improves on‑time, supporting more consistent functional ability. - Early-stage Parkinson's disease: provides symptomatic relief as an initial dopaminergic therapy, delaying the need for adjunctive treatments.

Madopar Hbs may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach often occurring at treatment initiation. - Dizziness: transient light‑headedness, especially when standing quickly. - Orthostatic hypotension: drop in blood pressure upon standing, may cause faintness. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation causing throat discomfort. - Constipation: slowed intestinal transit leading to hard stools.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome-like reactions: high fever, muscle rigidity, autonomic instability. - Severe psychiatric disturbances: hallucinations, delusions, or worsening psychosis. - Cardiac arrhythmias: rare cases of tachyarrhythmia. - Severe allergic reactions (anaphylaxis): rapid onset of hives, swelling, airway compromise. - Seizures: rare occurrence of convulsive episodes.

When prescribing Madopar Hbs, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: monitor blood pressure and heart rate, especially in patients with orthostatic hypotension risk. - Review psychiatric history: patients with psychosis may experience worsening symptoms. - Adjust dose in renal impairment: reduce dosage if severe renal dysfunction is present. - Evaluate hepatic function: use caution in patients with liver disease. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal or neuroleptic malignant syndrome‑like events. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Madopar Hbs can interact with several medications, altering its efficacy or increasing adverse effect risk.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: concurrent use can cause hypertensive crisis; avoid co‑administration. - Anticholinergic drugs (e.g., atropine, scopolamine): may diminish levodopa’s antiparkinson effect. - Antihypertensive agents (e.g., beta‑blockers): may potentiate orthostatic hypotension; monitor closely.

Moderate Interactions (Monitor Closely): - COMT inhibitors (e.g., entacapone): may increase levodopa plasma levels, requiring dose adjustment. - SSRIs and SNRIs: can enhance risk of serotonin syndrome when combined with MAO‑B inhibitors. - Diuretics: may exacerbate orthostatic hypotension; monitor blood pressure. - Iron supplements: reduce levodopa absorption if taken simultaneously; separate dosing by at least 2 hours.